Abbott Vascular is to stop selling their everolimus eluting bioresorbable scaffold across the globe on September 14, 2017. This decision was prompted by low commercial sales. At the time, this revolutionary technology offered patients the chance to avoid a permanent implant in their coronary arteries. However, it has clearly failed to meet the market’s expectations. Despite this…